Stephen Stamp

Biography

Stephen Stamp joined Ergomed in January 2016 as Chief Financial Officer and in December 2017 was also appointed Chief Executive Officer.Stephen brings to Ergomed more than 30 years of experience in corporate finance and general management in both public and private companies in the UK and the USA. Stephen joins Ergomed from US-based AssureRx Health, Inc, a personalised medicine and bio-informatics company where he was CFO. Prior to this he was CFO of EZCORP, Inc. (NASDAQ:EZPW), a consumer financial services company and Chief Operating Officer and CFO at Xanodyne Pharmaceuticals, Inc, a specialty pharmaceutical company. Before leaving for the US, Stephen was Group Finance Director at Shire Pharmaceuticals (LSE:SHP, NASDAQ:SHPG) where he led the IPO on London Stock Exchange as well as a number of major acquisitions and financings. During his time at the Company, Shire’s market capitalisation increased from GBP20 million to GBP3.1 billion. He was also Group Finance Director at Regus Plc (LSE:RGU) where he successfully listed the Company on London Stock Exchange Main Market and NASDAQ. Earlier in his career, Stephen was an investment banker with Lazard in London, advising mainly public companies on cross-border M&A and corporate finance. Prior to Lazard, he worked for KPMG in London where he qualified as a Chartered Accountant.

Research Interest

Accounts